LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Axsome Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

107.38 0.16

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

105.83

Max

108.7

Galvenie mērījumi

By Trading Economics

Ienākumi

15M

-59M

Pārdošana

2.7M

121M

EPS

-1.216

Peļņas marža

-48.914

Darbinieki

712

EBITDA

14M

-57M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+69.84% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 4. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-48M

5.4B

Iepriekšējā atvēršanas cena

107.22

Iepriekšējā slēgšanas cena

107.38

Ziņu noskaņojums

By Acuity

12%

88%

8 / 382 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Axsome Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. maijs 22:52 UTC

Peļņas
Galvenie tirgus virzītāji

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

2025. g. 15. maijs 20:37 UTC

Top Ziņas
Peļņas

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

2025. g. 16. maijs 00:00 UTC

Tirgus saruna

Xero Bull Stays Positive on Cost Outlook -- Market Talk

2025. g. 15. maijs 23:47 UTC

Tirgus saruna

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

2025. g. 15. maijs 23:38 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 15. maijs 23:38 UTC

Tirgus saruna

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

2025. g. 15. maijs 23:14 UTC

Top Ziņas

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

2025. g. 15. maijs 22:46 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

2025. g. 15. maijs 22:46 UTC

Iegādes, apvienošanās, pārņemšana

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025. g. 15. maijs 21:58 UTC

Peļņas

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

2025. g. 15. maijs 21:24 UTC

Peļņas

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

2025. g. 15. maijs 20:56 UTC

Tirgus saruna

U.S. Spending Downturn Could Lie Ahead -- Market Talk

2025. g. 15. maijs 20:54 UTC

Tirgus saruna
Peļņas

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

2025. g. 15. maijs 20:54 UTC

Peļņas

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

2025. g. 15. maijs 20:51 UTC

Peļņas

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

2025. g. 15. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. maijs 20:50 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

2025. g. 15. maijs 20:50 UTC

Peļņas

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

2025. g. 15. maijs 20:47 UTC

Peļņas

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

2025. g. 15. maijs 20:37 UTC

Peļņas

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

2025. g. 15. maijs 20:26 UTC

Top Ziņas

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

2025. g. 15. maijs 20:25 UTC

Peļņas

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Axsome Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

69.84% augšup

Prognoze 12 mēnešiem

Vidējais 176.07 USD  69.84%

Augstākais 210 USD

Zemākais 148 USD

Pamatojoties uz 16 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Axsome Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

16 ratings

16

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

107.24 / 112.29Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Neutral Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

8 / 382 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.